Spyre Therapeutics

Spyre Therapeutics

Biotechnology
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

$8B

Market Cap • 9/18/2026

2013

(13 years)

Founded

2016

(10 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

7,2

P/S

P/EBITDA

P/OCF

P/FCF

P/E

BVPS

14,7

EPS

Market Cap

Market Cap

8B

EV

7B

EV/Revenue

0

EV/EBITDA

-34,6

EV/EBIT

-34,6

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-9,8%

Total Yield

-9,8%

Payout

0%

Retained Earnings

-1,2B

Profitability

Gross Margin

EBITDA Margin

EBIT Margin

Net Margin

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

% PPE

0%

% Goodwill

0%

ROE

ROIC

Growth

CAGR Op. Income 5Y

25,1%

CAGR Net Income 5Y

22,1%

CAGR EPS 5Y

-40%

CAGR OCF 5Y

32%

Leverage

N.D./EBITDA

5,7

Debt/Equity

0%

Current Ratio

18,5

Quick Ratio

18,1

Interest Coverage

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium